Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. by Zweifel, Martin et al.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
DOI: 10.1530/EC-17-0174
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
6
6
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:6 549–556M Zweifel CR1447 in breast cancer
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
Open Access
Phase I trial of the androgen 
receptor modulator CR1447 in  
breast cancer patients
Martin Zweifel1, Beat Thürlimann2, Salome Riniker2, Patrik Weder2, 
Roger von Moos3, Olivia Pagani4, Martin Bigler5, Karin M Rothgiesser5, 
Christiane Pilop5, Hanne Hawle5, Peter Brauchli5, Coya Tapia6, 
Wolfgang Schoenfeld7 and Cristiana Sessa4 for the Swiss Group for Clinical Cancer 
Research (SAKK)
1Department of Medical Oncology, University Hospital Bern, Bern, Switzerland
2Breast Centre St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland
3Kantonsspital Graubünden, Chur, Switzerland
4Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
5SAKK Coordinating Centre, Bern, Switzerland
6Institute of Pathology, University of Bern, Bern, Switzerland
7CURADIS GmbH, Erlangen, Germany
Abstract
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has 
antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer 
cells in preclinical studies. The objective of this first-in man trial was to evaluate the 
safety and to determine the dose of CR1447, administered as an ointment, for Phase II. 
Escalating doses (100, 200, 400 mg) of CR1447 were administered topically on a daily 
basis to patients with ER-positive/AR-positive/HER2-negative advanced breast cancer 
pretreated with several lines of therapy. 14 patients have been treated for a total 
of 42 cycles. Two patients, one at dose level 100 mg and one at dose level 200 mg, 
showed early tumour progression and were replaced. Related adverse events were all 
≤ grade 2 and included fatigue, bone and joint pain, stiffness, dry skin and mouth, 
nausea, sweating, urinary tract infection, rash, headache and distress. No drug-related 
dose-limiting toxicities (DLTs) were seen. Two patients (17%) achieved stable disease at 
3 months. Pharmacokinetic analysis confirmed dose-dependent transdermal uptake of 
CR1447. 4-OH-androstenedione (4-OHA), a key metabolite of 4-OHT, was undetectable 
in most of the plasma samples. Urine metabolites of 4-OHT and 4-OHA indicate high 
exposure of 4-OHT after topical administration. Oestradiol serum concentrations did not 
increase, confirming preclinical data that CR1447 is not converted to estrogens in vivo. 
In conclusion, CR1447 administered transdermally as an ointment is well tolerated and 
appears to have single-agent activity in heavily pretreated ER-positive/HER2-negative 
breast cancer patients. The recommended phase II dose is 400 mg/day.
Introduction
For the treatment of breast cancer (BC), testosterone was 
already used extensively between the 1930s and 1960s 
with anecdotal tumour responses (especially in bone 
metastases) seen in up to 20% of treated women (1, 2, 
3, 4). Side effects such as hirsutism and other signs of 
virilisation in treated women and the evidence that 
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testosterone may be easily converted to estrogens in 
the body led to the discontinuation of its use (5). These 
findings suggest that selective androgen receptor (AR) 
modulators (SARMs) rather than testosterone may be used 
to treat AR-positive BC.
CR1447 (4-hydroxytestosterone (4-OHT)) is a steroidal 
small molecule with two distinct properties, acting as a 
steroidal aromatase inhibitor (AI) and binding to the 
AR with high affinity (IC50 4.4 nM) (6). In vitro studies 
indicate that human BC cell lines are inhibited by CR1447 
in their growth if they express the AR, while knockout 
of the AR abolishes this effect. A significant proportion 
of 4-OHT is converted to 4-hydroxyandrostenedione 
(4-OHA, formestane). In vivo, 4-OHT and 4-OHA form a 
redox reaction. 4-OHA is the 17-beta-oxidized isoform of 
CR1447. 4-OHA had previously been approved as an AI 
for the treatment of BC via intramuscular injection but 
was discontinued due to the development of oral AIs. 
Unlike testosterone, both compounds, 4-OHA and 4-OHT, 
are not converted to oestrogens in vivo (7, 8).
The combination of two mechanisms of action of 
CR1447 may result in higher activity. The objective of 
this phase I trial was to investigate the safety, tolerability, 
pharmacokinetics and the recommended dose (RD) of 
CR1447 for phase II in a clinical setting.
Patients and methods
CR1447
CR1447 was supplied in aluminium-coated stick packs as 
a 4 g ointment containing 2.5% of the active ingredient 
4-hydroxytestosterone (4-OHT). CR1447 stick packs had 
to be stored protected from light at room temperature 
and should neither be refrigerated or frozen nor heated 
over 30°C. CR1447 was supplied by CURADIS GmbH, 
Erlangen, Germany and distributed by Promedipharm 
GmbH, Germany.
Patients
Eligible patients were postmenopausal women with 
locally advanced or metastatic, histologically confirmed 
breast adenocarcinoma requiring therapy and not 
suitable for local treatment. Inclusion criteria were 
immunohistochemical oestrogen receptor (ER) positivity 
(≥1%) and/or progesterone receptor (PR) positivity (≥1%); 
in all cases, the tumour had to be human epidermal 
growth factor receptor 2 (HER2) negative. Presence of 
≥1 measurable or evaluable lesion according to RECIST 
1.1 was required. Bone metastases were allowed to be 
considered as target lesions in case of enhancement on 
scintigraphy, cytologic/histologic evidence or typical 
radiographic image. Patients with uncontrolled brain 
metastases, pulmonary carcinomatous lymphangiosis 
or liver metastases on >1/3 of the liver were not 
eligible. All patients gave written informed consent 
after full explanation of the purpose and nature of all 
procedures applied.
Study design and procedures
This four centre (Bern University Hospital; Istituto 
Oncologico della Svizzera Italiana, Bellinzona; 
Kantonsspital St. Gallen; and Kantonsspital Graubünden, 
Chur, Switzerland), first-in man, open-label, phase  I, 
dose escalation clinical trial (clinicaltrials.gov ID: 
NCT02067741) was reviewed by the Swiss Group 
for Clinical Cancer Research (SAKK) internal review 
process and approved by the Central and Local Ethics 
Committees and the Swiss Agency for Therapeutic 
Products (Swissmedic).
The main objective of the phase I was to determine 
safety, tolerability and the recommended dose (RD) 
of CR1447 for phase II, using a standard 3 + 3 dose 
escalation design.
Treatment consisted of CR1447 (provided in 100 mg 
stick packs) topically applied daily to the haunches and 
thighs until progression. One cycle was defined as lasting 
21 days. Three dose escalation steps (100, 200 and 400 mg 
daily) were performed including 3 patients in each dose 
cohort, with another 3 confirmatory patients in the last 
dose cohort or in case of a dose-limiting toxicity (DLT). 
A DLT was defined as an adverse event (AE), laboratory 
abnormality or a drug toxicity ≥ grade 3 that was 
considered to be probably, possibly or definitely related to 
the trial medication and which occurred during the first 
cycle of treatment. While 100 and 200 mg were applied 
once daily, 400 mg were applied as 200 mg twice daily at 
the same body site. The planned sample size was between 
2 and 18 evaluable patients. Since the overall toxicity of 
CR1447 was estimated to be low, the patients could switch 
to the next dose level when the next higher cohort of 3 
patients had finished first cycle treatment without DLTs. 
The dose was escalated to the next higher dose level, 
whenever 0 out of 3 or ≤1 out of 6 patients had a DLT. 
Patients were evaluated for DLT only at the lowest level 
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they had been treated. If no DLTs were to occur at the 
highest dose level, this level was determined to be the 
recommended dose for phase 2.
Dose modifications were planned for adverse events 
(AEs) grade 2 (dose reduction by one dose level) and 
grade 3 or 4 (stop treatment with CR1447 until resolved 
to grade ≤2 and restart one dose level lower until end of 
treatment). If an AE grade 3 or 4 occurred on an already 
reduced dose, CR1447 had to be stopped until the AE 
resolved to grade ≤2; treatment could then be resumed at 
one lower dose level.
Patients had to be taken off treatment if they missed 
≥7 days of treatment within the 1st cycle or >3 weeks of 
treatment within subsequent cycles.
Secondary endpoints were disease control at 24 weeks 
(DC24) i.e. complete remission (CR), partial remission 
(PR) and stable disease (SD) within the first 24 ± 2 weeks 
of treatment or stable disease (SD) for at least 24 weeks 
after treatment start; AEs; pharmacokinetic (PK) analysis 
of CR1447; pharmacodynamic (PD) analysis i.e. oestradiol 
levels during treatment; AR and Ki67 expression. Disease 
control at 12 weeks (DC12) was included as an additional 
secondary endpoint later on.
Pharmacokinetics (PK) and pharmacodynamics (PD)
Plasma and serum 4-OHT, 4-OHA (for PK) and oestradiol 
(for PD) concentrations were measured at baseline, after 
single dose administration at 1, 2, 4, 8, 24 and 72 h (day 
−7, −6, −5) and during treatment at 1, 8 and 15 days. Urine 
was collected from 0 to 8 h, and from 8 till 24 h after single 
administration of CR1447. Urine 4-OHT, 4-OHA (for PK) 
and oestradiol (for PD) concentrations were assessed at 
baseline, once at week 2 and once at week 3 of treatment.
High-pressure liquid chromatography with mass 
spectrometry (HPLC–MS) was used for the determination 
of 4-OHT and 4-OHA in human plasma, with 
testosterone-d3 and exemestane being used as internal 
standards, respectively. The lower limit of quantification 
of each analyte in plasma was 0.25 ng/mL.
Assessment of androgen receptor status
Central immunohistochemistry staining for the AR 
of the most recent formalin-fixed paraffin-embedded 
tissue samples was performed for all patients and scored 
semi-quantitatively. AR positivity was defined as any 
positive nuclear staining ≥1% in analogy to the College 
of American Pathologists’ (CAP) recommendations for 
reporting oestrogen receptor status (9). For every patient’s 
tumour tissue sample, percentage of AR-positive tumour 
cell nuclei and staining intensity, semi-quantitatively 
scored from 1 to 3, were determined.
Assessment of response
Best response was assessed by Response Evaluation 
Criteria in Solid Tumours (RECIST), version 1.1 (10). CT 
and bone scans were performed within 2 weeks prior to 
starting treatment at baseline, at week 12 (±8 days) and 24 
(±2 weeks). In case of radiologic response (i.e. CR or PR), 
a confirmatory scan had to be performed after 4  weeks 
(±8 days).
Data analysis and statistics
The primary DLT and MTD analysis was performed on all 
evaluable patients who signed the informed consent and 
who did not miss ≥7 days of treatment during the first 
cycle of treatment or had a DLT.
Other safety and efficacy data were analysed on all 
patients who received at least one dose of trial treatment.
Continuous data were summarised using median, 
minimum and maximum values. Categorical data were 
summarised using frequency and percentage.
Paired t test was used to compare the body weights of 
patients at the time of screening vs at the end of treatment.
Results
Between June 2014 and February 2015, fourteen patients 
were recruited onto the trial. Patient characteristics are 
listed in Table  1. Most patients presented with bone 
metastasis and all patients had received prior endocrine 
therapy. Two patients (one in dose level 1 and one in dose 
level 2) were not evaluable: one patient had progressive 
disease after two weeks of treatment; therefore, she was 
taken off trial since she missed ≥7  days of treatment. 
The other patient’s cancer progressed after two weeks 
of treatment and was taken off trial. Twelve patients 
completed the first cycle of therapy, three patients each at 
dose level 1 and 2 and six (three plus three confirmatory 
patients) at dose level 3. All fourteen patients were used 
for the analysis of toxicity and efficacy data.
All patients’ tumours stained positive for the AR 
(Table 2). Percentage of AR-positive nuclei ranged from 70 
to 100% and staining intensity from 2 to 3.
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Dose escalation and number of cycles administered 
are summarized in Table  3. Fourteen patients received 
a total of 42 cycles. Doses had to be modified in one 
cycle (6%) in the dose level 1 group, in one cycle (20%) 
in the dose level 2 group and in nine cycles (45%) in 
the dose level 3 group. The only dose reduction for 
toxicity reasons was made in one patient in the dose 
level 3 group for dry skin. Dose modifications are listed 
in Table 4.
Toxicity
Overall, 92 AEs (including blood count and chemistry 
changes) grade ≥1 according to NCI CTCAE, v4.0 occurred 
during treatment. The numbers of AEs per patient in the 
safety population that were possibly, probably or definitely 
drug related are summarised in Table 5.
Haematological toxicity was mild with only two 
patients experiencing grade 1/2 thrombocytopenia and 
one patient with grade 1 neutropenia. Anaemia was the 
most common haematological AE in 50% of patients, of 
which all were grade 1/2.
Elevated triglycerides were the most common blood 
chemistry AE in 57% of patients, of which all were grade 
1/2. Elevated liver function tests were seen in up to 50% 
of patients, including grade 3/4 toxicity. Renal function 
tests were elevated in 29% of patients, of which all were 
grade 1/2.
Drug-related non-haematological toxicity included 
rash and burning sensation of the skin in 14% of patients 
and dry skin in 21% patients. General symptoms included 
nausea and fatigue in 14% of patients each, sweating, 
headache, dry mouth, hot flashes and arthralgia in 7% 
of patients each. Bone pain and decreased joint range of 
motion occurred in 14% of patients each. One patient 
experienced a urinary tract infection and one patient 
suffered from agitation. All non-haematological AEs were 
grade 1/2. Occurrence of hirsutism was not observed. 
Body weight remained unchanged during treatment with 
CR1447. Mean body weight at screening was 69.36 kg 
(s.d. 15.93) compared to 69.71 kg (s.d. 15.34) at the end of 
treatment (P = 0.54).
Two serious adverse events (SAEs) were seen in this 
study. A 70-year-old patient in the dose level 2 group 
was admitted to the hospital with abdominal pain. Trial 
medication was discontinued and the patient died ten 
days later. Tumour progression was deemed the cause 
of death and the event was judged unrelated to the 
study medication. The second patient, a 54-year-old 
woman with brain metastases and a history of deep vein 
thrombosis, developed intracranial haemorrhage under 
anticoagulation with enoxaparin one month after starting 
on the trial. CR1447 was temporarily discontinued and 
enoxaparin was stopped. The patient recovered with 
residual symptoms of hemiplegia, but her tumour 
progressed and she was taken off trial. The event was 
judged unrelated to the study medication.
Response
Of the 14 patients, none achieved disease control (DC) at 
24 weeks. Two (14%) patients showed s.d. at 12 weeks; the 
first patient with s.d. at 12 weeks had previous treatment 
Table 1 Patient characteristics for the evaluable patients.*
Characteristics Count (n = 12)
Age (years)  
 Median 66
 Range 44–80
WHO performance status  
 0 8 (67%)
 1 4 (33%)
Prior therapy  
 Chemotherapy 10 (83%)
 Radiotherapy 7 (58%)
 Endocrine therapy 12 (100%)
Metastases  
 Bone 11 (92%)
 Liver 6 (50%)
 Lymph nodes 6 (50%)
 Lung 3 (25%)
 Skin 2 (17%)
 Brain 1 (8%)
*Two patients were not evaluable due to early progression within 
2 weeks after the start of study treatment and had to be replaced.
Table 2 Androgen receptor status upon immunohistochemistry.
Patient No. AR positive nuclei (%) AR staining intensity score
1 100 3
2 99 3
3 100 3
4 99 2
5 95 2–3
6 95 2
7 99 3
8 70 3
9 80 2
10 95 3
11 95 3
12 100 3
13 90 3
14 95 3
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with two lines of endocrine treatment (letrozole for 5 years 
in the adjuvant setting, followed by tamoxifen for 1 year 
in the palliative setting) and two lines of chemotherapy 
(cyclophosphamide, methotrexate and 5-fluorouracil, 
followed by epirubicin and cyclophosphamide); the 
second patient with s.d. at 12  weeks had two lines of 
endocrine treatment (tamoxifen for two years, followed 
by anastrozole for 7  months, both in the palliative 
setting). Eleven (79%) patients showed progressive disease 
and 1 (8%) patient’s response could not be assessed due to 
withdrawal of consent beforehand.
Pharmacokinetics
A total of 140 study test samples were analysed in order 
to determine 4-OHT and 4-OHA plasma concentrations.
Plasma concentrations after single dose administration 
of 100 mg CR1447 are shown in Fig. 1A. 4-OHT plasma 
concentrations were in the range of blq (below the lower 
limit of quantification) to 1.88 ng/mL. The Cmax and 
AUC values showed high inter-individual variability. 
Median Tmax (n = 12) for 4-OHT was 16 h (range: 1.0–72.0), 
median Cmax (n = 14) was 0.63 ng/mL (range: 0.0–1.88) 
and the median AUC0–72 (n = 12) was 27.2 h*ng/mL 
(range: 0.0–69.8).
The 4-OHA plasma concentrations were below the 
lower limit of quantification in all samples after single 
dose except for one sample tested.
Plasma concentrations after multiple dose 
administration of CR1447 are shown for 4-OHT in Fig. 1B 
and for 4-OHA in Fig. 1C. 4-OHT plasma concentrations 
on day 8 and day 15 were in the range of 0.37–2.81 ng/mL 
for dose level 100 mg, 0.72–5.61 ng/mL for dose level 
200 mg and 2.06–10.05 ng/mL for dose level 400 mg. 
4-OHA plasma concentrations on day 8 and day 15 
were in the range of blq to 0.34 ng/mL for dose level 
100 mg, blq to 0.89 ng/mL for dose level 200 mg and blq 
to 0.83 ng/mL for dose level 400 mg. 4-OHT and 4-OHA 
plasma concentrations increase with rising dose levels. 
No conclusions with regard to dose linearity can be 
drawn from these data, due to the high inter-individual 
variability and the limited number of data.
Table 3 Dose escalation and number of cycles administered.
 All patients (n = 14) Evaluable patients (n = 12)
 DL 1 (100 mg) DL 2 (200 mg) DL 3 (400 mg) DL 1 (100 mg) DL 2 (200 mg) DL 3 (400 mg)
No. of cycles 4 4 6 3 3 6
1 1 (25%) 3 (75%) 1 (17%) – 2 (67%) 1 (17%)
2 – 1 (25%) 3 (50%) – 1 (33%) 3 (50%)
3 – – – – – –
4 2 (50%) – – 2 (67%) – –
5 – – 1 (17%) – – 1 (17%)
6 – – – – – –
7 – – – – – –
8 1 (25%) – 1 (17%) 1 (33%) – 1 (17%)
Table 4 Dose deviations (all patients, n = 14).
 DL 1 DL 2 DL3
Cycles (n) 17 5 20
No deviation 16 (94%) 4 (80%) 11 (55%)
Physician’s choice – – 2 (10%)
Patient’s choice – – 6 (30%)
Toxicity – – 1 (5%)
Other* 1 (6%) 1 (20%) –
*Patients forgot taking the medication.
Table 5 Worst drug-related toxicity per patient (all cycles).
Adverse event Grade 1/2 Grade 3/4
Haematological and blood 
chemistry toxicity
  
 Elevated triglycerides 57% (8) –
 Elevated AST 29% (4) 21% (3)
 Anaemia 50% (7) –
 Elevated AP 29% (4) 14% (2)
 High creatinine 29% (4) –
 Elevated ALT 21% (3) 7% (1)
 Elevated bilirubin 7% (1) 14% (2)
 Thrombocytopenia 21% (3) –
 Neutropenia 7% (1) –
Rash, burning sensation 21% (3) –
Dry skin 21% (3) –
Nausea 14% (2) –
Fatigue 14% (2) –
Joint range of motion decreased 14% (2) –
Bone pain 7% (1) –
Dry mouth 7% (1) –
Sweating 7% (1) –
Urinary infection 7% (1) –
Headache 7% (1) –
Agitation 7% (1) –
Hot flashes 7% (1) –
Arthralgia 7% (1) –
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The cumulated amount of each analyte excreted in 
the urine (Ucum) was evaluated based on the individual 
urine concentrations of 4-OHT and 4-OHA (both, 
unchanged analyte, and following cleavage of the 
metabolite conjugates) and the total excreted volume 
within the sampling period following administration. 
The cumulated amounts (n = 14) are shown as medians 
in Table 6.
Pharmacodynamics of oestradiol
Serum oestradiol concentrations (pmol/L) after single 
dose administration of 100 mg 4-OHT (baseline to 72 h, 
n = 12) and during daily application of 100 mg 4-OHT 
(n = 3), 200 mg 4-OHT (n = 3) and 400 mg 4-OHT (n = 6), 
respectively (day 1, 8 and 15) are shown in Fig. 2. Median 
oestradiol serum concentrations did not increase over the 
time of 15 days.
Discussion
In preclinical studies, CR1447 has been shown to inhibit 
human BC cell lines in their growth if they express the 
AR, while knockout of the AR abolishes this effect. The 
antiproliferative activity of 4-OHT was assessed in nearly 
100 different experimental settings using different 
cell lines expressing the AR. Downregulation of the AR 
receptor by siRNA technology leads to a significant 
Figure 1
Plasma concentrations of 4-hydroxyandrostenedione (4-OHA) and 
4-hydroxytestosterone (4-OHT) after a single transdermal application of 
100 mg 4-OHT (72 h-pharmacokinetics, n = 12) (A). Plasma concentrations 
of 4-OHT after transdermal administration of 4-OHT at 100 mg/day 
(Group 1), 200 mg/day (Group 2) and 400 mg/day (Group 3) (B). Plasma 
concentrations of 4-OHA after transdermal administration of 4-OHT at 
100 mg/day (Group 1), 200 mg/day (Group 2) and 400 mg/day 
(Group 3) (C).
Table 6 Urine PK of 4-OHT and 4-OHA (n = 14).
 Ucum 0–24 (4-OHT) (nmol) Ucum 0–24 (4-OHA) (nmol) Ucum 0–24 (sum 4-OHT) (nmol) Ucum 0–24 (sum 4-OHA) (nmol)
Median (range) 2.42 (0.00–39.5) 0.49 (0.00–1.93) 8.72 (3.75–53.5) 34.5 (0.00–192)
Ucum, cumulative concentration in the urine; 4-OHT, 4-hydroxytestosterone; 4-OHA, 4-hydroxyandrostenedione.
Figure 2
Serum oestradiol concentrations (pmol/L) over the time of treatment with 
CR1447. The serum concentrations from baseline (BL) until 72 h were 
measured after single dose administration of 100 mg 
4-hydroxytestosterone (4-OHT) in 12 patients. The subsequent 
concentrations on days 1, 8 and 15 were measured during daily 
application of 4-OHT at three different doses, 100 mg (n = 3), 200 mg 
4-OHT (n = 3) and 400 mg 4-OHT (n = 6), respectively. Means (solid line) are 
given for all 12 patients at each time point. Dotted lines indicate 1st and 
3rd quartiles (the dotted 1st quartile line overlaps mostly with the solid 
mean line).
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reduction of the antiproliferative effects of 4-OHT (11). In 
this first-in man phase I trial, we investigated the toxicity, 
pharmacokinetics and pharmacodynamics of CR1447 in 
patients with ER-positive/AR-positive/HER2-negative BC.
Toxicity in general was mild. Anaemia was the most 
common haematological toxicity, while blood chemistry 
changes were observed mostly for triglycerides, liver and 
kidney function tests. While six out of seven patients who 
experienced liver and kidney function test impairment 
also suffered from liver metastasis, the finding of 
altered lipid profiles is not surprising. Based on previous 
experience with AIs, one might assume that CR1447 with 
its known AI activity may also elicit similar side effects 
(12). However, none of those led to dose modifications or 
disruptions regarding the treatment with CR1447 in our 
study. There is some controversy on the impact of AIs on 
the lipid profile. Lipid profile changes will need attending 
in future trials with CR1447.
Non-haematological toxicities included skin 
reactions/dry skin, which lead to a dose reduction in one 
patient only. These symptoms and other, less frequent 
ones such as nausea, fatigue, sweating, headache, bone 
and joint pain, dry mouth and hot flashes might fit well 
to the antihormonal effects of CR1447. All drug-related 
non-haematological toxicities were of grade 1/2 only.
The two serious adverse events (SAEs) seen in this 
study (death due to tumour progression and intracranial 
haemorrhage under anticoagulation) were judged 
unrelated to the study medication. No DLTs were seen.
The observation of two patients (17%) with stable 
disease after 12 weeks of treatment suggests some single-
agent activity, given that all patients received prior 
endocrine therapy, and 83% of these patients also had 
prior chemotherapy.
Recently, there has been a growing interest in 
targeting the AR in the treatment of BC. Clinical trials 
report a median progression-free survival of 12  weeks 
with the non-steroidal AR antagonists bicalutamide (13) 
and orteronel (14), but even complete responses have 
been observed (15). In a combination trial of the non-
steroidal AR antagonist enzalutamide with the oestrogen 
antagonist fulvestrant, 45% of patients still remained 
on treatment after 24  weeks (16). The non-steroidal AR 
modulator GTx-024 demonstrated clinical benefit in 35% 
of patients with metastatic BC at 6 months (17). Disease 
control at 12 weeks in our study is comparable with the 
results of the other studies cited. However, there are 
concerns that a pure antagonist could foster virilisation. 
Therefore, a partial antagonist, or selective androgen 
receptor modulator (SARM) such as the steroidal AR 
antagonist CR1447 might offer an advantage over the 
non-steroidal AR antagonists.
PK results confirmed a relatively quick absorption of 
4-OHT. One could have speculated that 4-OHT might be 
rapidly converted to 4-OHA in vivo, a drug which has been 
used previously as an AI (formestane, Lentaron). Formestane 
had to be given by intramuscular injection because of fast 
metabolisation if taken orally (18). Interestingly, our PK 
data show that the ratio of 4-OHT:4-OHA in the serum is 
roughly 10:1 even after two weeks of daily administration. 
However, the ratio of 4-OHT:4-OHA in urine is 1:5, possibly 
indicating metabolisation of 4-OHT to 4-OHA prior to 
and/or during elimination.
Serum oestradiol concentrations did not change 
during treatment with CR1447, indicating no relevant 
conversion of the drug to oestrogen.
The dose recommended for phase 2 trials must take 
account of the RECIST and toxicity data. As, due to the 
steroidal nature of the molecule, we did not anticipate 
issues with dose-related toxicity, we chose three different 
dose levels on the basis of preclinical studies and 
extrapolations from previous experience with 4-OHA. A 
relatively high number of cycles could be evaluated for 
toxicity (16 in DL1 vs 4 in DL 2 and 20 in DL3). CR1447 
was well tolerated at all dose levels, including the highest 
dose level at 400 mg/day.
In summary, CR1447 administered transdermally 
as an ointment was well tolerated and appears to have 
single-agent activity in heavily pretreated ER-positive/
AR-positive/HER2-negative BC patients. The next step 
will be a phase II trial in order to test the hypothesis if 
CR1447 might offer the possibility of non-chemotherapy-
based endocrine therapy to the limited treatment options 
in triple-negative (TN)/AR-positive BC. The recommended 
phase II dose is 400 mg/day.
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